Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Myosana Therapeutics

Request full access

Home | Myosana Therapeutics, Inc.

Seattle, United StatesFounded 2018Biotech & Life Sciences

About Myosana Therapeutics

Myosana Therapeutics is at the forefront of developing a groundbreaking gene therapy platform aimed at treating genetic muscle diseases. Founded in 2018 by Dr. Stan Froehner and Dr. Nick Whitehead, both renowned experts in neuromuscular disease, the company focuses on creating a non-viral, muscle-directed gene therapy. This innovative platform is designed to treat a wide range of neuromuscular disorders and cardiomyopathies, with an initial focus on Duchenne Muscular Dystrophy (DMD), a severe genetic disorder that leads to progressive muscle degeneration and weakness.

The company's business model revolves around research and development, targeting both the pharmaceutical and biotechnology markets. By pioneering a mutation-agnostic approach, Myosana's platform is applicable to patients with any mutation in the DMD gene, potentially transforming the lives of DMD patients and their families. Revenue is generated through partnerships, grants, and future commercialization of their gene therapy solutions.

Myosana Therapeutics serves a specialized client base, including patients suffering from genetic muscle diseases, healthcare providers, and research institutions. The company operates in the highly specialized field of gene therapy, focusing on neuromuscular and cardiac genetic diseases.

Source: Dealroom company data

Myosana Therapeutics in the Seattle ecosystem

Live from Dealroom

The Myosana Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed5 investors entered at this stage

  • Cure Duchenne
  • Parent Project Muscular Dystrophy
  • CureDuchenne Ventures
  • MDA Venture Philanthropy
  • John Ballantyne
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇬🇧 United Kingdom50%
🇺🇸 United States50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Myosana Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Myosana Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.